Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston's Liberte bare-metal stent:

This article was originally published in Clinica

Executive Summary

Boston Scientific has received Japanese approval for its bare-metal stent, Liberte, which also serves as the platform for the firm's second-generation paclitaxel-eluting stent, Taxus Liberte. "The approval of our Liberte stent represents an important step in the evolution of our drug-eluting stent (DES) programme in Japan," said Paul LaViolette, Boston's COO. The firm's Taxus Liberte has been CE-marked for sale in Europe since September 2005, and it hopes to launch the DES in the US during 2007. The firm is not yet ready to speculate on when the DES is likely to penetrate the Japanese market, but claims that it can now look forward to long-awaited Japanese approval of its first-generation Taxus Express 2 stent in mid-2007. Boston claims that Liberte provides physicians with enhanced lesion access in challenging anatomy due to its thin struts and highly flexible cell design.

You may also be interested in...

AAM Welcomes Proposal To Update Medicare Part D

After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.

Dr Reddy’s Wants To Break Into Top Five In India

Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.

Building Trust In Brands Should Be A Continuous Process For The Self-Care Industry

“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts